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Using quantitative phosphopeptide sequencing of unstimulated versus stimulated primary murine Foxp3+ regulatory and Foxp3− 
conventional T cells (Tregs and Tconv, respectively), we detected a novel and differentially regulated tyrosine phosphorylation site 
within the C1 domain of the guanine-nucleotide exchange factor CalDAG GEFI. We hypothesized that the Treg-specific and acti-
vation-dependent reduced phosphorylation at Y523 allows binding of CalDAG GEFI to diacylglycerol, thereby impacting the for-
mation of a Treg-specific immunological synapse. However, diacylglycerol binding assays of phosphomutant C1 domains of 
CalDAG GEFI could not confirm this hypothesis. Moreover, CalDAG GEFI−/− mice displayed normal Treg numbers in thymus and 
secondary lymphoid organs, and CalDAG GEFI−/− Tregs showed unaltered in vitro suppressive capacity when compared to CalDAG 
GEFI+/+ Tregs. Interestingly, when tested in vivo, CalDAG GEFI−/− Tregs displayed a slightly reduced suppressive ability in the 
transfer colitis model when compared to CalDAG GEFI+/+ Tregs. Additionally, CRISPR-Cas9-generated CalDAG GEFI−/− Jurkat 
T cell clones showed reduced adhesion to ICAM-1 and fibronectin when compared to CalDAG GEFI-competent Jurkat T cells. 
Therefore, we speculate that deficiency in CalDAG GEFI impairs adherence of Tregs to antigen-presenting cells, thereby impeding 
formation of a fully functional immunological synapse, which finally results in a reduced suppressive potential.
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Introduction
T cells need activation via their T cell receptor (TCR) 
through interaction with a peptide-loaded major histocom-
patibility complex (pMHC) expressed on the surface of an 
antigen-presenting cell (APC) in order to exert their re-
spective effector functions [1]. TCR stimulation is focused 
at the interface between T cells and APCs at the immuno-
logical synapse (IS), which is composed of the central su-
pramolecular activation cluster (cSMAC), surrounded by 
a peripheral (pSMAC) and distal SMAC (dSMAC). The 
SMACs are primarily comprised of microclusters of TCR/
CD3 molecules, integrin lymphocyte function-associated 
antigen-1 (LFA-1), and F-actin, respectively [2]. LFA-1 
plays a dual role during T cell activation at the IS: First, 
interaction of LFA-1 with its ligand intercellular adhesion 
molecule-1 (ICAM-1) stabilizes the specifi c IS structure, 
allowing fi rm adhesion and stable contacts, and thereby 
sensitizing the TCR for very low quantities of pMHC [2–
4]. Second, LFA-1 assists with integrin-mediated outside-
in signaling, which serves as feedback for the T cell and 
delivers environmental information about chemical and 
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mechanical characteristics; in this way, it supports intra-
cellular signaling processes and also enables the deactiva-
tion and decomposition of the IS [5]. Activation of LFA-1 
is facilitated in a three-step process. First, triggering of 
the TCR induces downstream signaling cascades, includ-
ing the generation of the second messenger molecules 
Ca2+ and DAG by phospholipase γ1 (Plcγ1). This results 
in activation of the small GTPase Rap1, a cellular switch 
regulating the transition from low to intermediate affi nity 
and clustering of LFA-1. Next, mechanical force generated 
through binding of LFA-1 to ICAM-1 promotes the fi nal 
conversion from the intermediate- to high-affi nity confor-
mation of LFA-1 [6–8].
Rap1 activation is initiated via one of its guanine-nu-
cleotide exchange factors, which include C3G, the CDM 
family member DOCK4, and Epac, PDZ-GEF or CalDAG 
GEF family members [9]. GEFs support the release of 
GDP bound by Rap1 and thereby enable binding of GTP, 
which activates Rap1. Functionally, Rap1 was shown to 
mediate extracellular regulated kinase (ERK1/2) activa-
tion and integrin-dependent cell adhesion as well as che-
mokine-induced migration in leukocytes [9].
The GEF CalDAG GEFI (Ca2+- and DAG-regulated 
guanine-nucleotide exchange factor I) is mainly expressed 
in the central nervous system, but it can also be found in 
cells of hematopoietic origin, such as T cells, platelets, 
and neutrophils [10–13]. Guanine-nucleotide exchange 
activity towards Rap1 is regulated via Ca2+ binding to the 
EF hand motifs of CalDAG GEFI [10]. However, the ac-
tual responsiveness of CalDAG GEFI towards the lipid 
second messenger DAG via its C1 domain remains con-
troversial [10, 14–16]. In human T cells, it was reported 
that CalDAG GEFI is activated upon TCR stimulation in 
a Plcγ1-dependent manner [11], and that it translocates to 
the cell membrane via interaction with polymerized actin, 
where it then colocalizes with Rap1 [14]. Besides TCR 
simulation, chemokine receptor activation such as the ac-
tivation of CXCR4 via SDF-1α (CXCL12) has also been 
shown to trigger CalDAG GEFI in T cells [15]. Due to 
the specifi city towards Rap1, CalDAG GEFI function also 
plays a role in the mechanisms of adhesion and migration. 
Elevated expression of CalDAG GEFI in Jurkat T cells 
leads to increased adhesion [11], and silencing of CalDAG 
GEFI in human primary T cells showed reduced adhesion 
following chemokine-mediated stimulation [15]. CalDAG 
GEFI-defi cient mice have diminished Rap1 activation and 
display impaired adhesion and migration properties in neu-
trophils. However, in CalDAG GEFI-defi cient platelets, 
Rap1 activation turned out to be delayed but robust later on, 
presumably owing to normal second-wave PKC-mediated 
activation [12, 13]. However, to the best of our knowledge, 
the role of CalDAG GEFI specifi cally in T cell subsets like 
regulatory T cells (Tregs) has not yet been thoroughly elu-
cidated. Importantly, CalDAG GEFI expression has so far 
only been detected in human T cells and has been consid-
ered to be absent in T cells from mice [5, 12].
Tregs play a crucial role in immune homeostasis and 
tolerance towards self and benign antigens and are defi ned 
by the expression of the master transcription factor Foxp3 
[17–21]. Disruption of the Foxp3 locus leads to fatal au-
toimmunity in mice and humans, which manifests in the 
scurfy phenotype and immune dysregulation, polyendocri-
nopathy, enteropathy, and X-linked (IPEX) syndrome [22, 
23]. It was already reported that the IS of Tregs and their 
counterparts, the conventional T cells (Tconv), differs with 
regard to the spatiotemporal distribution of some of the 
main molecular players like PKCθ [24], and that signaling 
downstream of TCR ligation, e.g., Ca2+ fl ux or phosphory-
lation of ERK, contrasts Tregs with Tconv [25–27].
The present study is based on a recently performed 
comparative proteome and phosphoproteome analysis of 
primary murine Tregs and Tconv, which not only revealed 
differential expression of CalDAG GEFI within these two 
T cell subsets, but also identifi ed a novel phosphorylation 
site within CalDAG GEFI that is differentially regulated 
between Tregs and Tconv upon stimulation. While lipid-
binding assays excluded an infl uence of the phosphoryla-
tion status of CalDAG GEFI on its DAG responsiveness, 
adhesion properties of CalDAG GEFI−/− Jurkat T cells 
were signifi cantly impaired. Phenotyping of the T cell 
compartment of CalDAG GEFI−/− mice displayed nor-
mal T cell development and homeostasis, and CalDAG 
GEFI−/− Tregs exhibited unaltered suppressive capacity in 
vitro. However, CalDAG GEFI−/− Tregs showed a slightly 
reduced suppressive capacity in vivo in mice, which might 
be due to impaired IS formation between Tregs and APCs 
based on compromised LFA-1 activation.
Materials and methods
Mouse strains
BALB/c were purchased from Harlan or Janvier. CalDAG 
GEFtm1Amg. (129S4-Sv/Jae) and Rag2−/− (C57BL/6) mice 
were bred, housed and handled under specifi c pathogen-
free conditions at the Helmholtz Centre for Infection Re-
search (Braunschweig, Germany). Mice used in transfer 
colitis experiments were gender and age matched.
Antibodies and flow cytometry
Exclusion of dead cells was facilitated by LIVE/DEAD 
Fixable Dead Cell Stain (Invitrogen) prior to surface and 
intracellular staining or using propidium iodide in unfi xed 
samples. Foxp3 staining was carried out employing Foxp3 
staining kit (eBiosciences). Fluorochrome-conjugated an-
ti-CD3 (clone 17A2), anti-CD4 (clone RM4-5), anti-CD8 
(clone 53-6.7), anti-CD25 (clone PC61.5), anti-CD62L 
(clone MEL-14), anti-CD44 (clone IM7), anti-CD103 
(clone 2E7), anti-CD152 (clone UC10-4B9), anti-Foxp3 
(clone FJK-16S), anti-human CD3 (clone OKT3), anti-
human CD11a (clone HI111), and anti-human CXCR4 
(clone 12G5) were purchased from Biolegend or eBiosci-
ences. Data acquisition was performed using LSRII SORP 
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or LSR Fortessa equipped with Diva software (BD Biosci-
ences). Cell sorting was performed on Aria II SORP (BD 
Biosciences) or MoFlo XDP (Beckman Coulter). For data 
analysis, FlowJo software (TreeStar) was used.
Proteome and quantitative phosphopeptide sequencing
Tregs and Tconv were profi led by proteome and quanti-
tative phosphopeptide sequencing (van Ham et al., under 
preparation). In brief, CD4+CD25+ Tregs and CD4+CD25− 
Tconv were ex vivo isolated from single cell suspensions 
of pooled spleen and lymph node (LN) cells from BALB/c 
mice by MACS-based enrichment of CD4+ T cells using 
direct beads (L3T4, Miltenyi Biotec) followed by fl ow 
cytometry-based sorting to high purity. For proteome 
analysis, sorted T cell subsets were left unstimulated. For 
quantitative phosphopeptide sequencing, cells were either 
left unstimulated or stimulated by decoration with bioti-
nylated anti-CD3 (clone145-2C11, BD Biosciences) and 
anti-CD28 (clone 37.51, BD Biosciences) and subsequent 
antibody crosslinking using streptavidin. Stimulation was 
stopped after 5 min with an excess of ice cold PBS and 
cells were further processed for liquid chromatography – 
tandem mass spectrometry (LC–MS/MS) (further experi-
mental details available on request).
Western blot
CD4+CD25+ Tregs and CD4+CD25− Tconv were ex vivo 
isolated as described above. Primary T cell subsets or Jur-
kat T cells were lysed in RIPA lysis buffer (50 mM Tris-
HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 
1% NP40, 0.1 mM PMSF, Roche Complete Mini Protease 
Inhibitor), and total protein concentration was determined 
via BCA assay following the manufacturer’s instructions 
(Thermo Scientifi c). PVDF membranes were blocked us-
ing blotting-grade milk powder and specifi c protein bands 
were detected via anti-Rasgrp2 (GTX108616, Genetex), 
anti-β-actin (AC-74, Sigma), or anti-phosphotyrosine 
(4G10, Upstate) with appropriate secondary antibodies 
and Super Signal West Dura Extended Duration Substrate 
(Thermo Scientifi c).
Protein expression, purification, and lipid-binding assay
For expression of recombinant GST-fused C1 do-
main, the coding sequence of the C-terminal region 
of murine CalDAG GEFI (corresponding to amino 
acids 495-553) was amplifi ed using forward primer 
5ʹGAATTCATGGGCTTCGTACACAACTTC, reverse 
primer 5ʹCTCGAGCTGGGCGCGGCGACA, and Phu-
sion Flash II DNA polymerase. The PCR product was 
digested with EcoRI/XhoI and subcloned into pGEX-
4T-1, and the fi nal construct was verifi ed by sequencing. 
Phosphomutant C1 constructs were generated utilizing 
the Q5® Site-Directed Mutagenesis Kit (NEB) (Y523D: 
forward primer 5ʹCCTGGGCATCGACAAGCAGGG, 
reverse primer 5ʹATCAGAGCTTTGCAGTGGC; Y523F: 
forward primer 5ʹCTGGGCATCTTCAAGCAGGGC, re-
verse primer 5ʹGATCAGAGCTTTGCAGTGG) accord-
ing to the manufacturer’s instructions. For expression, the 
respective plasmids were transformed into Escherichia 
coli BL21. At an optical density of 0.7–0.9 at 600 nm, 
1 mM isopropylthio-β-galactoside was utilized for induc-
tion. Cells were lysed, recombinant proteins were puri-
fi ed via GSH columns and dialyzed against PBS or PBS 
supplemented with 100 μM ZnCl2. Prior to lipid-binding 
assay, protein concentration was determined via BCA as-
say (Thermo Scientifi c), and 0.5 μg/ml of each protein was 
tested on membrane lipid PIP Strips (Echelon) following 
the manufacturer’s instructions.
CRISPR-Cas9-mediated gene knock-out in Jurkat T cells
Single guide RNAs (sgRNA) targeting CalDAG GEFI 
in Jurkat T cells were generated utilizing the online 
tool http://crispr.mit.edu/ (Zhang Lab, MIT, 2015). Se-
lected sgRNAs were cloned into pSpCas9(BB)-2A-GFP 
(Addgene plasmid no. 48138) via BbsI restriction site; 
pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng 
Zhang [28]. Jurkat T cells (JE6) were cultured in RPMI 
(Gibco) supplemented with 10% of fetal calf serum (FCS, 
Biochrom). For transfection, Jurkat T cells were electro-
porated employing the Amaxa Cell Line Nucleofector V 
Kit and the Amaxa Nucleofector device. Forty-eight hours 
after nucleofection, single Jurkat T cells were sorted into 
96-well round bottom plates according to GFP expression. 
Single cell clones were expanded and tested for CalDAG 
GEFI expression via Western Blot.
Transduction of Jurkat T cells
To reexpress CalDAG GEFI in CalDAG GEFI−/− Jur-
kat T cell clones, lentiviral transduction was employed 
utilizing a modifi ed version of pRRL-PPT-SF-IRES-
EGFP-PRE [29]. To allow effi cient and site-directed 
cloning of cDNAs upstream of the IRES sequence, a 
multiple cloning site (MCS) was introduced via overlap-
ping PCR into pRRL-PPT-SF-IRES-EGFP-PRE [29]. 
Using the latter as a template, intermediate overlapping 
PCR products A and B were generated by using primer 
pairs MCS-For and RRL-ApaI-Rev (5ʹACTAGTTC
GACGCGTCAAATCTAGATTATCGATACCGGTG
ACGGATCCGCCC CTCTCCCTCCCCCCCCC and 
5ʹCAGGTTTCCGGGCCCTCACATTGCCAAA) as well 
as MCS-Rev and RRL-PstI-For (5ʹCACCGGTATCGATA
ATCTAGATTTGACGCGTCGAACTAGTCTGTCGGA
GGAC TGGCGCGCCGAGTGAGG and 5ʹTAGCCTCG
AGCTAGCTGCAGTAACGCCA), respectively. The  fi nal 
product C was obtained by using overlapping products A 
and B as templates and fl anking primers RRL-PstI-For 
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and RRL-ApaI-Rev. Finally, product C was subcloned, 
sequenced, and cloned into pRRL-PPT-SF-IRES-EGFP-
PRE by ApaI and PstI restriction enzymes, resulting 
in pRRL-PPT-SF-newMCS-IRES-EGFP-PRE. For vi-
rus particle production, HEK293T cells were transfected 
with pRRL-PPT-SF-newMCS-i2-EGFPpre (empty vector 
back bone as control or vector containing subcloned hu-
man CalDAG GEFI) as well as packaging and envelope 
plasmids, employing calcium phosphate coprecipitation. 
Virus supernatant (VSN) was collected and concentrated 
via overnight centrifugation. For transduction, 2 × 106 Jur-
kat T cells were resuspended in 2 ml of enriched VSN and 
centrifuged for 30 min at 800 g. VSN was aspirated, and 
Jurkat T cells were cultured for 72 h in RPMI with 10% 
FCS before functional assays were performed. Transfec-
tion and transduction effi ciencies were assessed via GFP 
expression of HEK293T and Jurkat T cells, respectively.
Adhesion and migration assays
JE6 or CalDAG GEFI−/− Jurkat T cells were adjusted to 
1 × 105 cells/ml in RPMI with 10% FCS one day before the 
experiment. To study cell adhesion, on the experimental 
day, cells were stimulated with 5 μg/ml anti-CD3 (OKT3, 
BD Biosciences), 50 ng/ml PMA (Calbiochem), or 1 mM 
MnCl2 for 30 min at 37 °C before adhesion on Fc-ICAM-
1-coated (0.5 μg/well, R&D system) or Fibronectin-coated 
(1 μg/well, Roche) 96-well plates. 2 × 105 cells were seed-
ed per well, and adhesion was allowed for 30 min at 37 °C. 
Unbound cells were removed by gently washing three 
times with HBSS (Biochrom AG), and the bound cell frac-
tion was determined by counting using an ocular reticle. 
Bound cells were calculated as “% of input” in duplicates. 
Migration assays were performed using 5 μm polycarbon-
ate fi lter transwells (Costar) coated with 20 μg/ml fi bro-
nectin (1 h 37 °C, Roche). The lower transwell chamber 
was fi lled with either migration assay medium (RPMI, 1% 
bovine serum albumin fraction V, 10 mM HEPES pH 7.4) 
or migration assay medium supplemented with 200 ng/ml 
human SDF-1α (CXCL12, Biolegend). 2 × 105 cells were 
added to the upper chamber in 200 μl migration assay me-
dium, and after 2.5 h at 37 °C, the number of migrated 
cells into the lower chamber was counted.
Phosphotyrosine analysis
Total CD4+ T cells were isolated from spleen and LNs of 
CalDAG GEFI−/−, CalDAG GEFI+/− and CalDAG GEFI+/+ 
mice using mouse CD4 DirectBeads (L3T4) and the au-
toMACS separation system (Miltenyi Biotec). For stimu-
lation, 1 × 106 cells were resuspended in complete RPMI 
(cRPMI; 10% FCS, 25,000 Units penicillin/25 mg strep-
tomycin, 1 mM sodium pyruvate, 25 mM HEPES, 50 μM 
β-mercaptoethanol) supplemented with either 20 ng/ml 
PMA and 1 μg/ml ionomycin (both from Sigma) or 35 μM 
sodium pervanadate (Sigma), and incubated for 5 min at 
37 °C. For anti-CD3/CD28 stimulation, cells were coated 
with 20 μg/ml biotinylated anti-CD3 (clone 145-2C11, BD 
Biosciences) and 10 μg/ml biotinylated anti-CD28 (clone 
37.51, BD Biosciences), and crosslinking was induced for 
5 min by addition of 10 μg/ml streptavidin in cRPMI. As 
stimulation controls, cells were either left on ice or incu-
bated at 37 °C for 5 min in cRPMI. Following stimulation, 
cells were washed once in ice-cold PBS, and cell pellets 
were further processed for lysis and Western Blotting.
Phosflow staining for phospho-ERK1/2
Cells from spleen and LNs of CalDAG GEFI−/−, CalDAG 
GEFI+/− and CalDAG GEFI+/+ mice were stained for dead 
cells using the LIVE/DEAD Fixable Dead Cell Stain (In-
vitrogen) and subsequently for surface markers CD4 and 
CD25. Next, cells were coated with 10 μg/ml biotinylated 
anti-CD3 (clone 145-2C11, BD Biosciences) and 5 μg/ml 
biotinylated anti-CD28 (clone 37.51, BD Biosciences) for 
15 min on ice. After removal of excess antibody, cells were 
pre-warmed to 37 °C and stimulation was initiated by ad-
dition of 10 μg/ml streptavidin in cRPMI. After indicated 
time points, cells were fi xed (BD Biosciences Phosfl ow 
Lyse/Fix) and permeabilized (BD Biosciences Phosfl ow 
Perm Buffer III) according to the manufacturer’s proto-
col. Cells were stained intracellularly for ERK1/2 pT202/
pY204 or isotype control (both BD Biosciences Phosfl ow) 
and Foxp3 at 4 °C overnight.
In vitro suppression assay
CD4+CD25+ Tregs were sorted from spleen and LNs of 
CalDAG GEFI−/−, CalDAG GEFI+/− and CalDAG GEFI+/+ 
mice as described above. Sorted cells were pre-activated 
for 72 h by stimulation on plate-bound anti-CD3/CD28. 
For antibody coating, wells were incubated overnight at 
4 °C with 50 μg/ml goat fraction to hamster IgG (MP Bio-
medicals), washed with PBS, and subsequently incubated 
for 1 h at 4 °C with 1 μg/ml anti-CD3 (clone 145-2C11, Bi-
olegend) and 3 μg/ml anti-CD28 (clone 37.51, Biolegend). 
Sorted cells were cultured in cRPMI supplemented with 
40 ng/ml IL-2 (R&D). Freshly sorted and Cell Trace™ 
Violet (CTV, Invitrogen)-labeled Tnaive (CD4+CD25−
CD62Lhigh) from CalDAG GEFI+/− mice were cocultured 
with pre-activated Tregs at indicated ratios in presence 
of T activator Beads (Life Technologies) in a ratio of one 
bead to two cells. On day four, CTV dilution was deter-
mined in living Tnaive by fl ow cytometry.
Transfer colitis
Freshly sorted Tregs and Tnaive from CalDAG GEFI−/− 
and CalDAG GEFI+/+ were washed in PBS, and a total of 
4 × 105 cells was injected intraperitoneally into Rag2−/− re-
cipient mice in a ratio of 1:2 or 1:4 (Tregs:Tnaive). Body 
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weight and health status of recipient mice was monitored 
biweekly over 10 weeks, and mice that lost >20% of ini-
tial body weight were sacrifi ced. For analysis, colon was 
rolled into a “Swiss roll”, fi xed in 4% neutrally buffered 
formaldehyde, and embedded in paraffi n. Approximately 
3-μm-thick sections were stained with hematoxylin/eo-
sin (H&E) according to standard laboratory procedures. 
Slides were evaluated in a manner that was randomized 
and blinded to the experimental groups. A semi-quantita-
tive score was applied for the marker’s severity, lympho-
cytic invasion, epithelial hyperplasia, single cell apop-
tosis, and area involved. Each marker was graded from 
0 to 3 as follows: Severity: 0 = no alteration, 1 = mild 
alteration, no serious disruption of the normal architec-
ture, 2 = moderate alteration, but normal architecture of 
the epithelium still visible, 3 = severe infl ammation dis-
turbing the entire epithelial structure, transmural. Lym-
phocytic infi ltration: 0 = no lymphocytes in lamina pro-
pria, 1 = few cells in lamina propria, not interfering with 
crypt structure, 2 = moderate amount of cells in lamina 
propria, increasing thickness of the crypts in max. 50%, 
3 = transmural invasion of infl ammatory cells, exceeds 
2. Hyperplasia: 0 = no alteration, 1 = up to 50% increase 
in crypt length, 2 = 50–100% increase in crypt length, 
moderate disturbance of crypt architecture, 3 = more than 
100% increase in crypt length and marked disturbance of 
crypt architecture. Single cell apoptosis: 0 = no apoptosis 
observed, 1 = max. 1 per crypt, 2 = 2–3 per crypt, 3 = 
exceeds 2. Area involved: 0 = no alteration, 1 ≤ 40%, 2 
= 40–70%, 3 ≥ 70%. The grades for these markers were 
added together for a total score of 0–15.
Statistical analysis
Prism software (GraphPad) was employed for generation 
of graphs and statistical analysis. Data points in scatter 
plots represent individual mice. If not stated otherwise, 
data are represented as mean ± SD. Statistical signifi -
cance was determined via Mann–Whitney test or one-way 
ANOVA (Bonferroni’s multiple comparison test or Krus-
kal–Wallis with Dunn’s test for multiple comparison). *p < 
0.05 was considered signifi cant with *p < 0.05, **p < 0.01, 
and ***p < 0.001.
Ethics
Animals were handled with appropriate care and welfare 
in accordance with good animal practice as defi ned by 
FELASA and the national animal welfare body GVSO-
LAS under supervision of the institutional animal welfare 
offi cer, and all efforts were made to minimize suffering. 
Animal experiments were performed in accordance with 
institutional, state, and federal guidelines, and all animal 
experiments were approved by the Lower Saxony Com-
mittee on the Ethics of Animal Experiments as well as 
the responsible state offi ce (Lower Saxony State Offi ce of 
Consumer Protection and Food Safety) under the permit 
number 33.92-42502-04-13/1170.
Results
CalDAG GEFI is phosphorylated at Y523 and becomes 
dephosphorylated in Tregs upon TCR stimulation
CalDAG GEFI is known to have an impact on LFA-1 ac-
tivation, showing responsiveness to both TCR and che-
mokine receptor triggering in human T cells [11, 14, 15]. 
However, the role of CalDAG GEFI in murine T cells and 
particularly in Tregs has not been studied so far, as no ex-
perimental evidence was available, showing that CalDAG 
GEFI is expressed in T cells from mice [5, 12]. Interest-
ingly, we could detect CalDAG GEFI expression in ex 
vivo-isolated murine Tregs and Tconv during a recently 
performed comparative proteome study (manuscript un-
der preparation), with a slightly higher expression level 
in Tconv (Fig. 1a), a fi nding that could be confi rmed by 
Western Blot analysis (Fig. 1b). Quantitative phospho-
peptide sequencing of unstimulated versus stimulated 
Tregs and Tconv within the same study (van Ham et al., 
under preparation) even led to the identifi cation of a novel 
phosphorylation site within the C-terminal C1 domain of 
CalDAG GEFI at Y523 (Fig. 1c). In resting Tregs, Y523 
phosphorylation is slightly reduced as compared to resting 
Tconv. This difference becomes more pronounced upon 
TCR stimulation via crosslinked anti-CD3/CD28. Normal-
ization to unstimulated Tconv shows that, while in Tconv 
Y523 phosphorylation is not responsive to TCR stimula-
tion, the site gets strongly dephosphorylated in Tregs upon 
TCR triggering (Fig. 1c,d). Thus, we confi rm here that 
CalDAG GEFI is expressed at detectable levels in murine 
T cell subsets and we could identify a novel phosphory-
lation site located in the C1 domain that is differentially 
regulated downstream of TCR signaling in primary murine 
Tregs and Tconv.
Phosphorylation status of Y523 does not affect DAG 
binding of CalDAG GEFI C1 domain
Although it is well established that generally C1 do-
mains bind DAG, it is not clear whether the C1 domain 
of CalDAG GEFI is responsive to this lipid second mes-
senger or any of its derivatives, such as PMA [14, 30–33]. 
Recently, Czikora et al. showed that the C1 domain of hu-
man CalDAG GEFI binds DAG with very low affi nity, if 
it indeed binds at all, which they primarily attribute to four 
amino acid residues, namely N505, S506, A517, and I519 
[16]. As Y523 is in close proximity to these crucial ami-
no acid residues that comprise part of the DAG-binding 
pocket, we wondered whether the phosphorylation status, 
which affects the local charge of the evolutionary con-
served C1 domain (Fig. 1e), infl uences the DAG-binding 
ability of CalDAG GEFI.
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To address this question, we cloned WT and two phos-
phomutant murine C1 domain constructs (Y523D and 
Y523F) into pGEX-4T-1, which adds an N-terminal GST-
tag. Recombinant proteins were expressed in E. coli BL21, 
purifi ed via sepharose, and eluted to high purity. We applied 
equal amounts of purifi ed proteins to membrane lipid PIP 
Strips and detected protein binding to the spotted lipids via 
the GST-tag. For both mutated C1 domain versions, Y523D 
and Y523F, no DAG binding could be detected (Fig. 2a). 
To support proper protein folding and stability, purifi ed C1 
domains were dialyzed against ZnCl2-containing buffer; 
however, this treatment did not result in any DAG bind-
Fig. 1. CalDAG GEFI is expressed in primary murine Tregs and Tconv and is differentially phosphorylated upon TCR ligation. A 
comparative proteomic analysis of FACS-sorted primary murine Tregs and Tconv was performed and found CalDAG GEFI expres-
sion in both T cell subsets. (a) Representative MS/MS spectra of one of the identifi ed iTRAQ-labeled peptides of murine CalDAG 
GEFI (Tregs 115.1 green, Tconv 117.1 yellow) and (b) Western blot for CalDAG GEFI from FACS-sorted primary murine Tregs and 
Tconv. β-Actin served as loading control. Quantitative phosphopeptide sequencing of unstimulated or anti-CD3/28 stimulated primary 
murine Tregs and Tconv identifi ed a novel phosphorylation site within CalDAG GEFI at Y523. (c) Representative MS/MS spectra of 
the iTRAQ-labeled peptide of CalDAG GEFI, which covers the newly identifi ed phosphorylation site at Y523 (iTRAQ ions: 114.1 
resting Tregs, red; 115.1 resting Tconv, green; 116.1 activated Tregs, blue; 117.1 activated Tconv, yellow). The phosphorylation is ap-
parent from the 80 Da difference in molecular weight of the peptide y2 (534.2 Da) as compared to peptide y2 in Fig. 1a (454.3 Da). 
The phosphorylation site Y523 is differentially regulated in primary Tregs and Tconv, especially following TCR triggering. (d) Direct 
comparison of the phosphorylation level of Y523 in resting (0ʹ) and 5 min activated Tregs and Tconv (5ʹ) revealed a reduced phos-
phorylation level of this site in Tregs when compared to Tconv, which becomes more pronounced after TCR ligation. (e) Comparison 
of the C1 domain protein sequence of CalDAG GEFI shows a high degree of conservation between humans and mice. Amino acids 
which were previously described to be important for DAG binding of C1 domains of CalDAG GEF family members are depicted as 
bold letters, and the newly identifi ed phosphorylated residue Y523 is highlighted in red
Fig. 2. Substitutions of CalDAG GEFI Y523 do not affect DAG binding of the C1 domain. The infl uence of the phosphorylation status 
of Y523 within the CalDAG GEFI C1 domain on binding to DAG was assessed. Membrane lipid PIP strips of recombinantly ex-
pressed and purifi ed WT C1, phosphomimetic Y523D C1 and Y523F C1 domain, which represents the dephosphorylated state, as well 
as the manufacturer’s positive control (+ control), are depicted. The tested proteins did not show binding to DAG (squares), neither (a) 
in absence nor (b) in presence of ZnCl2, which aids in proper protein folding. Variation in background staining is in accordance with 
the methodology; a positive signal is attributed to an intense signal covering the full lipid spot (see + control). Data are representative 
of two independent experiments
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ing of the phosphomutant versions of CalDAG GEFI C1 
domain (Fig. 2b). Therefore, we conclude that the observed 
differential phosphorylation of CalDAG GEFI Y523 in 
activated murine Tregs versus Tconv has no impact on 
CalDAG GEFI’s sensitivity towards DAG.
CalDAG GEF−/− Jurkat T cells display slightly reduced 
TCR-induced adhesion to ICAM-1 and fibronectin
but unaffected CXCR4-mediated migration
We generated two CalDAG GEFI−/− Jurkat T cell lines 
utilizing the CRISPR-Cas9 technology with transient ex-
pression of EGFP reporter protein, sgRNA and SpCas9 
protein. Single GFP+ Jurkat T cells were FACS-sorted 
into 96-well plates and subsequently expanded. Loss of 
CalDAG GEFI expression in two established lines, name-
ly, 2D5 (hereafter referred to as no. 1) and 3D6 (no. 2), 
was verifi ed via Western blot analysis (Suppl. Fig. 1a). 
CalDAG GEFI is implemented into signaling pathways 
leading to LFA-1 activation, and it was previously shown 
that siRNA-based silencing of CalDAG GEFI expression 
in Jurkat T cells impairs cell adhesion [15]. Therefore, we 
tested adhesion of CalDAG GEFI-defi cient Jurkat T cell 
clones to ICAM-1 and fi bronectin in comparison to WT 
Jurkat T cells (JE6). As expected, unstimulated Jurkat 
Fig. 3. CalDAG GEFI−/− Jurkat T cells show slightly reduced adhesion but unaffected migration properties. Two CalDAG GEFI−/− 
Jurkat T cell clones were generated and tested for adhesion to ICAM-1 and fi bronectin as well as for migration on fi bronectin to-
wards a chemoattractant. To rescue adhesion and/or migration abnormalities caused by CalDAG GEFI knock-out, both CalDAG 
GEFI−/− clones were reconstituted with wildtype CalDAG GEFI. Transduction with empty vector backbone served as treatment con-
trol. CalDAG GEFI-competent JE6 Jurkat T cells (JE6, white bars) or CalDAG GEFI−/− clones (no. 1, grey bars, and no. 2, black 
bars), untransduced (−), empty vector transduced (EV) or CalDAG GEFI reexpressing (WT), were either left unstimulated (unstim) 
or were stimulated via anti-CD3 (TCR) or MnCl2 (MnCl2) to induce adhesion to (a) ICAM-1 or (b) fi bronectin. (c) JE6 and CalDAG 
GEFI−/− clones, untransduced and transduced, were tested for migration without chemoattractant (medium) or towards SDF-1α. Data 
are pooled from three to fi ve independently performed experiments (mean ± SD)
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T cells showed very little adhesion, while nearly 60% of 
MnCl2-treated cells attached to ICAM-1 and fi bronec-
tin irrespective of CalDAG GEFI defi ciency. Defi ciency 
of CalDAG GEFI led to signifi cantly reduced adhesion 
of TCR-triggered Jurkat T cells to both ICAM-1 and fi -
bronectin (Fig. 3a,b). Importantly, this phenotype could 
be reverted and rescued upon lentiviral reexpression of 
CalDAG GEFI (WT), while transduction with an empty 
control vector (EV) did not show any effect (Fig. 3a,b). 
As it was already reported that LFA-1 activation is also 
required for CXCR4-mediated chemotaxis towards 
SDF-1α [34], we next analyzed the impact of CalDAG 
Fig. 4. Thymic T cell development and peripheral T cell homeostasis are unaffected by CalDAG GEFI defi ciency. Flow cytometry data 
of the T cell compartment of single cell suspensions from (a, b) thymus and (c, d) pooled spleen and LNs from CalDAG GEFI+/+ (WT), 
CalDAG GEFI+/− (HET), and CalDAG GEFI−/− (KO) mice. (a) Exemplary dot plots show CD4 versus CD8 expression on gated living 
thymocytes (left) and Foxp3 versus CD25 expression on gated CD4SP thymocytes (right). (b) Scatter plots summarize frequencies of 
DN, DP, CD8SP, total CD4SP, Foxp3−CD4SP, and Foxp3+CD4SP thymocytes from CalDAG GEFI+/+ (WT), CalDAG GEFI+/− (HET), 
and CalDAG GEFI−/− (KO) mice (n = 11–21 per group). (c) Exemplary dot plots show CD3 expression on gated living pooled spleen 
and LN cells (left), CD4 versus CD8 expression on gated CD3+ cells (middle) and CD25 versus Foxp3 expression on gated CD3+CD4+ 
cells (right). (d) Scatter plots summarize frequencies of CD3+, CD8+, total CD4+, Foxp3−CD4+, and Foxp3+CD4+ cells from pooled 
spleen and LN cells from CalDAG GEFI+/+ (WT), CalDAG GEFI+/− (HET), and CalDAG GEFI−/− (KO) mice (n = 11–24 per group). 
Mean of each group is depicted, and each data point represents a single mouse
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GEFI expression on the migration capability of Jurkat 
T cells. In absence of a chemoattractant, all analyzed cells 
showed comparable basal migration (Fig. 3c). However, 
in the presence of SDF-1α, both CalDAG GEFI−/− clones 
showed slightly diminished migration towards the che-
mokine, which could not be rescued by reexpression of 
CalDAG GEFI (Fig. 3c), suggesting that this phenotype 
is clone-specifi c and not due to CalDAG GEFI defi ciency. 
To rule out the possibility that reduced adhesion and mi-
gration of CalDAG GEFI−/− clones are due to a reduction 
in surface expression of molecules that are involved in 
the respective signaling pathways, we analyzed protein 
abundance of CD3, the LFA-1 component CD11a, and the 
SDF-1α receptor CXCR4 on JE6 Jurkat T cells and both 
CalDAG GEFI−/− clones via fl ow cytometry. No signifi -
cant differences in surface expression of CD3 and CXCR4 
could be detected, and reexpression of CalDAG GEFI by 
lentiviral transduction had no infl uence on these mol-
ecules (Suppl. Fig. 1b,c,e). However, differences could 
be observed with regard to CD11a, whose expression was 
signifi cantly reduced on clone no. 1 independent of the 
lentiviral reexpression (Suppl. Fig. 1d). Taken together, 
we conclude that the drop in surface levels of CD11a is 
biologically irrelevant in the experimental settings used 
Fig. 5. Signal transduction is comparable in CD4+ T cells from CalDAG GEFI+/+ and CalDAG GEFI−/− mice. Phosphorylation of 
ERK was assessed by fl ow cytometry of bulk CD4+ T cells, which were stimulated via crosslinking of biotinylated anti-CD3/CD28 
via streptavidin over a time course of 5 min. Tconv and Tregs were gated separately according to Foxp3 expression. (a) Graphs sum-
marize frequencies of pERK+ cells at indicated time points for Tconv (upper panel) and Tregs (lower panel) (mean ± SD; n = 10 mice 
per group); CalDAG GEFI+/+ (WT, open circles) and CalDAG GEFI−/− (KO, closed circles). (b) Total CD4+ cells from spleen and LNs 
from CalDAG GEFI+/+ (WT), CalDAG GEFI+/− (HET), and CalDAG GEFI−/− (KO) mice were stimulated for 5 min, and total phos-
phorylated tyrosine residues (pY) were analyzed via Western blot. As stimulation controls, cells were either kept on ice or incubated 
for 5 min at 37 °C. Activation of cells was carried out via crosslinking of biotinylated anti-CD3/CD28 via streptavidin (αCD3/28), 
PMA, or pervanadate (Na3VO4). β-Actin served as loading control. Exemplary Western blots from three independent experiments are 
shown
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in the present study to analyze cell adhesion and chemo-
taxis, suggesting that loss of CalDAG GEFI impairs LFA-
1-dependent adhesion of Jurkat T cells to ICAM-1 and 
fi bronectin following TCR triggering, whereas CXCR4-
mediated migration remains unaffected.
CalDAG GEFI−/− mice display normal thymic T cell
development and T cell homeostasis in secondary
lymphoid organs
To address the role of CalDAG GEFI in murine T cells 
apart from the differential phosphorylation dynamics at 
Y523 in Tregs, we analyzed the T cell compartment within 
CalDAG GEFI−/− mice, which had been previously report-
ed to have defects in platelet aggregation and neutrophil 
migration [12, 13]. In these initial studies, the lymphocyte 
count appeared to be normal, although the T cell compart-
ment was not analyzed in detail [12]. Here, we fi rst ana-
lyzed the thymic T cell compartment and did not observe 
any overt effect of CalDAG GEFI defi ciency on T cell 
development, as double negative (DN), double positive 
(DP), CD8 single positive (CD8SP), and CD4 single posi-
tive (CD4SP) fractions were found in comparable frequen-
cies in CalDAG GEFI−/− (KO), CalDAG GEFI+/− (HET), 
and CalDAG GEFI+/+ (WT) mice (Fig. 4a,b). Similarly, no 
differences in frequencies of Foxp3+ and Foxp3− CD4SP 
thymocyte subsets were found (Fig. 4a,b), and also the 
two Treg precursors identifi ed as CD25+Foxp3− or CD25−
Foxp3+ cells [35, 36] were present at comparable frequen-
cies (data not shown). To assess the impact of CalDAG 
GEFI defi ciency on T cell homeostasis in the periphery, 
we analyzed the T cell compartment in pooled spleen and 
LNs and observed no differences in frequencies and ab-
solute numbers of CD3+, CD4+, CD8+, CD4+Foxp3−, and 
CD4+Foxp3+ T cell subsets in WT, HET, and KO mice 
(Fig. 4c,d, and data not shown). We conclude that defi -
ciency of CalDAG GEFI affects neither thymic develop-
ment nor peripheral homeostasis of T cells.
TCR downstream signaling is not affected by loss
of CalDAG GEFI
It was previously reported that CalDAG GEFI affects 
ERK1/2 activation via Rap1, and, more specifi cally, it 
Fig. 6. CalDAG GEFI−/− Tregs are suppressive in vitro. Ability of Tregs from CalDAG GEFI+/+ and CalDAG GEFI−/− mice to suppress 
proliferation of bead-stimulated Tnaive from CalDAG GEFI+/− in vitro was compared. (a) Exemplary histogram plots show dilution 
of the proliferation dye cell trace violet (CTV) of bead-stimulated sorted Tnaive cells. Tnaive cells were cultured without addition of 
Tregs and without T activator beads (unstimulated) as negative proliferation control (far left). Coculture of Tnaive and Tregs at indicat-
ed ratios (Tregs: Tnaive at 0:1, 1:1, 1:8 and 1:32), including a constant number of T activator beads, displays comparable suppressive 
capability of CalDAG GEFI+/+ (WT, upper panel) and CalDAG GEFI−/− (KO, lower panel) Tregs. Numbers indicate geometric mean 
(Geomean) of the respective signal intensity of CTV gated on total Tnaive cells. (b) Mean and standard deviation of the Geomean of 
CTV of Tnaive cocultured with CalDAG GEFI+/+ (WT, open circles) and CalDAG GEFI−/− (KO, closed circles) Tregs. Data are pooled 
from three independently performed experiments (mean ± SD)
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was shown that CalDAG GEFI reduces Elk1 activation 
and thereby limits ERK1/2 phosphorylation [9–11, 37]. 
As it is also known that Tregs display attenuated pERK1/2 
levels as compared to Tconv [26, 27, 38], we sought to 
address the role of CalDAG GEFI in TCR downstream 
signaling in ex vivo isolated Tregs and Tconv. To this end, 
we stimulated total CD4+ T cells from pooled spleen and 
LNs of CalDAG GEFI−/− (KO) or CalDAG GEFI+/+ (WT) 
mice via crosslinking of anti-CD3/CD28. At various time 
points following stimulation, we measured pERK1/2 via 
fl ow cytometry in Foxp3+ and Foxp3− CD4+ T cell sub-
sets. As expected, ERK1/2 phosphorylation was induced 
rapidly upon TCR ligation in both Tregs and Tconv, with 
Tconv reaching higher frequencies of pERK+ cells when 
compared to Tregs (Fig. 5a,b). Interestingly, CalDAG 
GEFI defi ciency did not affect ERK1/2 phosphorylation 
signifi cantly, neither in Tconv nor in Tregs, although a 
trend towards reduced ERK1/2 phosphorylation was ob-
served in Tconv from CalDAG GEFI-defi cient mice (KO) 
(Fig. 5a). To get a more global picture on the impact of 
CalDAG GEFI on TCR downstream signaling events, we 
next analyzed total tyrosine phosphorylation patterns by 
Western blotting in stimulated total CD4+ T cells ex vivo 
isolated from pooled spleen and LNs of CalDAG GEFI−/− 
(KO), CalDAG GEFI+/− (HET), and CalDAG GEFI+/+ 
(WT) mice. Isolated cells were stimulated via crosslinking 
anti-CD3/CD28 for 5 min, and stimulations using PMA/
ionomycin or sodium pervanadate were taken as positive 
controls. Unstimulated cells, which were either kept on ice 
or incubated in medium only, did not show any signs of 
tyrosine phosphorylation (Fig. 5b). For none of the tested 
stimulation conditions (anti-CD3/CD28, PMA/ionomy-
cin, or sodium pervanadate), major differences in tyrosine 
phosphorylation could be observed when KO, HET, and 
WT CD4+ T cells were compared, while expected altera-
tions in overall signal strength according to the respective 
stimulation condition were apparent (Fig. 5b). Thus, in our 
experimental setting, CalDAG GEFI is largely dispensable 
for TCR downstream signaling within primary murine 
CD4+ T cells.
CalDAG GEFI−/− Tregs display normal suppressive
capacity in vitro
To assess the suppressive capacity of CalDAG GEFI−/− 
Tregs in vitro, CD4+CD25+ Tregs were sorted from 
pooled spleen and LNs of CalDAG GEFI−/− or CalDAG 
GEFI+/+ mice and pre-activated in presence of IL-2 for 
72 h on plate-bound anti-CD3/CD28. Subsequently, pre-
activated Tregs were cocultured with cell trace violet-
labeled Tnaive (CTV) freshly isolated from CalDAG 
GEFI+/− mice in titrated ratios in presence of anti-CD3/
CD28-coated beads. At day 4 of the coculture, prolifera-
tion of Tnaive was measured by analyzing CTV dilution 
via fl ow cytometry. As expected, unstimulated Tnaive did 
not proliferate and showed a high CTV fl uorescence sig-
nal, while stimulated Tnaive in the absence of Tregs (0:1) 
proliferated substantially and diluted the dye progres-
sively with every generation (Fig. 6a,b). Upon addition 
of Tregs, a dose-dependent suppressive activity could 
be observed; however, no difference was apparent when 
Tregs from CalDAG GEFI−/− (KO) and CalDAG GEFI+/+ 
(WT) mice were directly compared (Fig. 6b). Foxp3 
staining on the day of analysis revealed equal survival 
and stability of CalDAG GEFI−/− and CalDAG GEFI+/+ 
Tregs in the respective cultures (data not shown). In 
conclusion, CalDAG GEFI defi ciency does not alter the 
suppressive ability of the Tregs in this APC-free in vitro 
system. However, since CalDAG GEFI plays a crucial 
role in LFA-1 activation and this integrin has an impor-
tant function in the formation of the IS between T cells 
and APCs, the effect of CalDAG GEFI defi ciency on the 
suppressive capacity of Tregs might rely on their interac-
tion with APCs.
CalDAG GEFI−/− Tregs are less capable to prevent
intestinal inflammation in the transfer colitis model
To evaluate the suppressive capacity of CalDAG GEFI−/− 
Tregs under more physiological conditions, we chose the 
transfer colitis model, which is widely used to assess the 
suppressive capacity of Tregs. As expected, Rag2−/− re-
cipient mice receiving only Tnaive from CalDAG GEFI+/+ 
mice developed signs of colitis as evidenced by body 
weight loss starting from week 5 to 6 after T cell trans-
fer (Suppl. Fig. 2a), shortening of colon length (Suppl. 
Fig. 2b), and a strong colonic pathology when compared 
to control mice receiving PBS only (Fig. 7). Cotrans-
fer of Tnaive with CD4+CD25+ Tregs at a ratio of 1 : 2 
(Treg : Tnaive) resulted in a mild, but substantial amelio-
ration of intestinal infl ammation regarding all parameters 
tested; however, no differences could be observed between 
Tregs isolated from CalDAG GEFI−/− (KO) or CalDAG 
GEFI+/+ (WT) mice (Fig. 7a, Suppl. Fig. 2a,b). According-
ly, fl ow cytometric analysis of the T cell compartment in 
spleen, mLNs, and pLNs at the termination of the experi-
ment did not show any differences in frequencies and ab-
solute numbers of CD3+CD4+, CD4+CD44+CD62L− mem-
ory T cells, CD4+Foxp3+ Tregs, and CD4+Foxp3− Tconv, 
as well as CD103 and CTLA-4 expression on Tregs (data 
not shown).
Next, we tested a lower ratio between Tregs and Tnaive 
(1:4), which has been used previously to detect subtle dif-
ferences in the suppressive capacity of Treg subsets [39, 
40]. Again, no differences with regard to body weight loss 
and colon length could be observed between the groups of 
mice receiving WT or KO Tregs (Suppl. Fig. 2c,d). Howev-
er, analysis of colonic pathology revealed that Tregs from 
CalDAG GEFI−/− mice had a slightly reduced suppressive 
capacity when compared to Tregs from CalDAG GEFI+/+ 
mice (Fig. 7b). Together, we conclude that CalDAG GEFI 
defi ciency mildly affects the suppressive capacity of Tregs 
in vivo, with this phenotype only becoming apparent under 
weak suppression conditions.
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Discussion
CalDAG GEFI is known to be important for human T cell 
adhesion [15]. Yet, it has not been investigated whether it 
also has a specifi c role in Foxp3+ Tregs. In the present study, 
we report on a novel phosphorylation site at Y523 within 
the C1 domain of mouse CalDAG GEFI, which upon stim-
ulation is differentially regulated in ex vivo isolated mu-
rine Tregs when compared to Tconv. T cell development 
and homeostasis in secondary lymphoid organs, as well 
as ERK phosphorylation, are all unaffected in CalDAG 
GEFI−/− mice, and general signal transduction as seen by 
tyrosine phosphorylation patterns in total CD4+ T cells is 
also unchanged. Although CalDAG GEFI−/− Jurkat T cells 
showed normal chemotaxis behavior when compared to 
CalDAG GEFI-expressing Jurkat T cells, their adhesion to 
ICAM-1 and fi bronectin was impaired. These data corre-
spond nicely to the assessment of the suppressive capacity 
of CalDAG GEFI−/− Tregs, which showed a normal inhi-
bition of Tnaive proliferation in an APC-free in vitro as-
say, while a reduced suppressive capacity was observed at 
weak suppression conditions in vivo.
The CalDAG GEF family comprises four members, 
CalDAG GEFI-IV [12, 41–44]. Although CalDAG GEFI 
is not the most prominent family member to be found 
in T cells, in a recently performed study, we identifi ed a 
novel phosphorylation site in CalDAG GEFI, which is 
located within its C-terminal C1 domain at Y523. Quan-
titative phosphopeptide sequencing comparing unstimu-
lated and TCR-stimulated primary murine Tregs and 
Tconv revealed that Y523 phosphorylation is not affected 
by TCR stimulation in Tconv, whereas this site becomes 
strongly dephosphorylated upon TCR ligation in Tregs. 
As there is a growing body of evidence that TCR down-
stream signaling is distinctively organized in Tregs and 
Tconv [24, 26, 27, 38], we speculated whether this dif-
ferential phosphorylation fosters a differential activation 
of the two T cell subsets while also promoting the forma-
tion of a Treg-specifi c IS. The specifi c kinase responsible 
for phosphorylating CalDAG GEFI at Y523 and which 
phosphatase dephosphorylates it upon TCR ligation spe-
cifi cally in Tregs remain unidentifi ed, and further stud-
ies are needed for their identifi cation. In contrast to the 
other family members, CalDAG GEFI contains an atypi-
cal C1 domain, and it is currently debated whether this 
C1 domain can bind DAG itself, or simply DAG deriva-
tives such as PMA [14, 16, 30–33, 45]. Czikora et al. re-
ported that the C1 domain of human CalDAG GEFI binds 
DAG with very low affi nity [16]. They could identify 
four critical amino acids within the C1 domain, which 
were essential for conformational stability of the binding 
pocket and its ability to retain a phorbol ester within this 
pouch. These exact amino acids are N505, S506, A517, 
and I519, which are replaced by N505T, S506Y, A517G, 
and I519L within the C1 domain of CalDAG GEFII and 
enable DAG responsiveness of this GEF [16]. The impor-
tance of the residue S506 was also previously addressed 
by Johnson et al.; however, they came to the conclusion 
that amino acid variations alone cannot account for the 
total loss of phorbol ester binding [45]. As the differen-
tially phosphorylated Y523 localized into the loop B of 
the phorbol ester-binding pouch, we speculated that the 
negative charge of the phosphogroup also contributes to 
the inability to bind DAG, and that DAG responsiveness 
of CalDAG GEFI might be restored in Tregs upon remov-
al of the phosphorylation after TCR triggering, leaving 
the hydrophobic tyrosine as a suitable environment for 
lipid binding. We generated a phosphomimetic mutant, 
Y523D, and a mutant representing the dephosphorylated 
state, Y523F, of the C1 domain, and tested for DAG bind-
ing via membrane lipid PIP strips. As all of the mutant C1 
domains showed detectable binding, the functional role 
of the differentially regulated phosphorylation at Y523 in 
Tconv and Tregs might be related to activation of the pro-
Fig. 7. Suppressive capacity of CalDAG GEFI−/− Tregs is slightly reduced in an in vivo model of transfer colitis. Capability of Tregs 
from CalDAG GEFI+/+ and CalDAG GEFI−/− mice to suppress colon infl ammation in vivo after cotransfer with Tnaive from CalDAG 
GEFI+/+ into lymphopenic Rag2−/− mice was tested. PBS was injected as negative control (PBS). Eight to 10 weeks after T cell transfer, 
sections from colons were H&E stained and scored for severity of infl ammation with a maximum score of 15. Rag2−/− mice received 
Tnaive from CalDAG GEFI+/+ mice alone (no Tregs) or plus Tregs from either CalDAG GEFI+/+ (WT Tregs) or CalDAG GEFI−/− (KO 
Tregs) mice at a ratio of (a) 1:2 or (b) 1:4 (Tregs:Tnaive). Means of histology scores within the indicated experimental groups are shown 
with each data point representing an individual mouse (pooled data from two independent experiments; n = 6–10 mice per group).
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tein or interaction with other molecules, and needs to be 
addressed in future experiments.
We detected impaired adhesion of CalDAG GEFI−/− 
Jurkat T cell clones to ICAM-1 and fi bronectin following 
TCR stimulation, and this phenotype could be reverted by 
reexpression of CalDAG GEFI. The observed decline in 
adhesiveness following TCR triggering was not due to dis-
turbed expression of CD3, which could have accounted for 
impaired stimulation resulting in decreased integrin acti-
vation. Furthermore, although we saw a signifi cant reduc-
tion in surface expression of CD11a on one of the CalDAG 
GEFI−/− Jurkat T cell clones, this observation was not in-
fl uenced by reexpression of CalDAG GEFI. Therefore, we 
conclude that this phenotype was clone-specifi c and did 
not affect adhesion properties. Our fi nding that CalDAG 
GEFI plays a role in cell adhesion following TCR ligation 
is in line with published data showing CalDAG GEFI-me-
diated cell adhesion to ICAM-1 after SDF-1α stimulation 
[15]. In contrast to adhesion, chemokine-triggered migra-
tion of CalDAG GEFI−/− Jurkat T cells on fi bronectin was 
not affected. Although a slightly lower number of migrat-
ing cells was observed for CalDAG GEFI−/− clones in the 
present study, the difference did not reach statistical signif-
icance and was not infl uenced by reexpression of CalDAG 
GEFI. Thus, we speculate that CalDAG GEFI plays a role 
in adhesion and stable IS formation in murine T cells, but 
is dispensable for migration processes and hemisynapse 
formation [2].
In CalDAG GEFI−/− mice, platelets display a reduced 
activation of Rap1, as well as defi cits in attachment and 
thrombus formation due to impaired αIIβ3 and β1 integrin 
activation [12, 13, 46]. Furthermore, neutrophils of this 
mouse line are defective in migration, which was also at-
tributed to reduced Rap1, β1 and β2 integrin activation, as 
well as decreased integrin and L-selectin expression [13, 
46]. Lymphocyte counts appeared to be normal [12], and 
CalDAG GEFI−/− mice are lacking any obvious T cell-re-
lated phenotype. In line with these previously published 
general observations, more thorough examination of the 
T cell compartment within the thymus and secondary 
lymphoid organs confi rmed that T cell development and 
homeostasis are not disturbed in CalDAG GEFI−/− mice, 
suggesting that, in T cells, CalDAG GEFI defi ciency can 
be compensated for by other GEFs, like C3G [9, 47], and 
might play non-redundant roles only in specifi c cell types 
and/or under certain perturbations.
Several in vitro studies proposed a role for CalDAG 
GEFI in ERK1/2 activation [10, 11, 48]. Kawasaki et al. 
found that overexpression of CalDAG GEFI in 293T cells 
inhibits Elk1 activation and assumed that this would lead 
to reduced phosphorylation of ERK1/2 further down-
stream [10]. In this case, knock-out of CalDAG GEFI 
should result in elevated pERK1/2 levels, although this hy-
pothesis could not be confi rmed utilizing primary murine 
CD4+ T cells from CalDAG GEFI−/−, CalDAG GEFI+/−, 
and CalDAG GEFI+/+ mice in the present study. Generally, 
we could not detect a direct link between loss of CalDAG 
GEFI expression in murine CD4+ T cells and any impair-
ment of signal transduction. A more recent publication 
described a negative feedback loop, in which ERK1/2 
phosphorylates CalDAG GEFI at S394, which in turn 
auto-inhibits its GEF activity towards Rap1, ultimately 
also reducing phosphorylation of ERK1/2 [48]. However, 
in our phosphoproteomic approach, we could not identify 
any phosphorylation of S394, indicating that, under the ap-
plied stimulation conditions, ERK1/2 does not phosphory-
late S394 in murine CD4+ T cells.
CalDAG GEFI-defi cient Tregs showed a comparable 
suppressive capacity as Tregs from WT mice when tested 
in vitro, suggesting that the mere absence of this mol-
ecule does not dramatically affect the functional proper-
ties of these cells in an APC-free system. However, when 
CalDAG GEFI-defi cient Tregs were tested in vivo under 
conditions that allow detection of subtle differences in the 
suppressive capacity of Treg subsets [39, 40], a slightly re-
duced inhibition of intestinal infl ammation was observed 
when compared to WT Tregs, indicating that CalDAG 
GEFI fi ne-tunes the functional properties of Tregs, most 
likely through the modulation of aggregate formation be-
tween Tregs and APCs, a process known to strongly affect 
the suppressive function of Tregs [49].
In conclusion, our data suggest that CalDAG GEFI is 
dispensable for LFA-1 activation during migratory pro-
cesses in CD4+ T cells, but is crucial for fi ne-tuning LFA-1 
activation at the IS. Whether the differential phosphoryla-
tion at Y523 in Tconv and Tregs contributes to the for-
mation a Tregs-specifi c IS needs to be addressed in future 
studies.
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